Last reviewed · How we verify
IN10018 in combination with D-1553
IN10018 in combination with D-1553 is a Small molecule drug developed by InxMed (Shanghai) Co., Ltd.. It is currently in Phase 3 development for Advanced or metastatic solid tumors (indication under phase 3 investigation).
IN10018 in combination with D-1553 represents a dual-targeted immunotherapy approach designed to enhance anti-tumor immune responses through complementary mechanisms.
IN10018 in combination with D-1553 represents a dual-targeted immunotherapy approach designed to enhance anti-tumor immune responses through complementary mechanisms. Used for Advanced or metastatic solid tumors (indication under phase 3 investigation).
At a glance
| Generic name | IN10018 in combination with D-1553 |
|---|---|
| Sponsor | InxMed (Shanghai) Co., Ltd. |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
While specific details on IN10018 and D-1553 individually are limited in public literature, combination immunotherapies typically work by targeting distinct immune checkpoints or pathways to overcome resistance and amplify T-cell activation. This combination approach aims to improve efficacy over single-agent therapy by engaging multiple immune regulatory pathways simultaneously.
Approved indications
- Advanced or metastatic solid tumors (indication under phase 3 investigation)
Common side effects
Key clinical trials
- a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors (PHASE1, PHASE2)
- A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (PHASE3)
- Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IN10018 in combination with D-1553 CI brief — competitive landscape report
- IN10018 in combination with D-1553 updates RSS · CI watch RSS
- InxMed (Shanghai) Co., Ltd. portfolio CI
Frequently asked questions about IN10018 in combination with D-1553
What is IN10018 in combination with D-1553?
How does IN10018 in combination with D-1553 work?
What is IN10018 in combination with D-1553 used for?
Who makes IN10018 in combination with D-1553?
What development phase is IN10018 in combination with D-1553 in?
Related
- Manufacturer: InxMed (Shanghai) Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Advanced or metastatic solid tumors (indication under phase 3 investigation)
- Compare: IN10018 in combination with D-1553 vs similar drugs
- Pricing: IN10018 in combination with D-1553 cost, discount & access